StocksFundsScreenerSectorsWatchlists
CDMO

CDMO - Avid Bioservices Inc Stock Price, Fair Value and News

6.76USD-0.22 (-3.15%)Delayed as of 28 Mar 2024, 02:01 pm ET

Market Summary

CDMO
USD6.76-0.22
Delayedas of 28 Mar 2024, 02:01 pm
-3.15%

CDMO Stock Price

View Fullscreen

CDMO RSI Chart

CDMO Valuation

Market Cap

441.4M

Price/Earnings (Trailing)

-38.55

Price/Sales (Trailing)

3.13

EV/EBITDA

678.78

Price/Free Cashflow

-7.89

CDMO Price/Sales (Trailing)

CDMO Profitability

Operating Margin

60.74%

EBT Margin

-8.22%

Return on Equity

-6.23%

Return on Assets

-2.52%

Free Cashflow Yield

-12.67%

CDMO Fundamentals

CDMO Revenue

Revenue (TTM)

140.9M

Rev. Growth (Yr)

-26.94%

Rev. Growth (Qtr)

-32.69%

CDMO Earnings

Earnings (TTM)

-11.4M

Earnings Growth (Yr)

-722.58%

Earnings Growth (Qtr)

-354.32%

Breaking Down CDMO Revenue

52 Week Range

7.11
(Low)(High)

Last 7 days

7.0%

Last 30 days

-10.3%

Last 90 days

3.4%

Trailing 12 Months

-62.2%

How does CDMO drawdown profile look like?

CDMO Financial Health

Current Ratio

1.35

CDMO Investor Care

Shares Dilution (1Y)

1.49%

Diluted EPS (TTM)

-0.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023140.7M149.3M150.3M140.9M
2022116.0M119.6M125.5M134.2M
202180.8M95.9M101.2M106.3M
202064.2M59.7M69.8M72.6M
201943.5M53.6M56.3M64.4M
201864.6M53.6M39.1M36.5M
201758.5M57.6M79.1M68.5M
201635.2M44.7M40.6M54.5M
201523.9M26.8M31.0M34.2M
201420.2M22.4M23.2M22.2M
201319.5M21.7M22.1M23.3M
201215.9M15.2M13.8M15.7M
201117.1M13.5M15.9M15.5M
2010027.9M24.3M20.7M

Tracking the Latest Insider Buys and Sells of Avid Bioservices Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 12, 2024
kwietniak matthew r.
sold
-1,854
6.77
-274
chief commercial officer
Jan 11, 2024
kwietniak matthew r.
acquired
-
-
669
chief commercial officer
Jan 10, 2024
richieri richard a.
sold
-6,509
6.17
-1,055
chief operations officer
Jan 10, 2024
hart daniel r
sold
-14,856
6.1697
-2,408
chief financial officer
Jan 10, 2024
kwietniak matthew r.
sold
-6,539
6.1698
-1,060
chief commercial officer
Jan 10, 2024
ziebell mark r
sold
-8,304
6.17
-1,346
v. p., general counsel
Jan 10, 2024
richieri richard a.
sold
-715
6.17
-116
chief operations officer
Jan 09, 2024
kwietniak matthew r.
acquired
-
-
2,533
chief commercial officer
Jan 09, 2024
ziebell mark r
acquired
-
-
3,208
v. p., general counsel
Jan 09, 2024
richieri richard a.
acquired
-
-
2,512
chief operations officer

1–10 of 50

Which funds bought or sold CDMO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-80.86
-165,274
25,084
-%
Mar 11, 2024
VANGUARD GROUP INC
reduced
-18.28
-18,274,900
23,516,200
-%
Mar 08, 2024
ICA Group Wealth Management, LLC
new
-
13,559
13,559
-%
Mar 05, 2024
Fisher Asset Management, LLC
unchanged
-
-670,497
1,482,390
-%
Mar 05, 2024
GREENWOOD CAPITAL ASSOCIATES LLC
sold off
-100
-294,415
-
-%
Mar 04, 2024
VIMA LLC
new
-
6,832
6,832
0.02%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
338
5,532,480
8,270,330
-%
Mar 01, 2024
Pineridge Advisors LLC
new
-
1,677
1,677
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-9.48
-121,171
200,506
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
reduced
-88.82
-172,000
14,000
-%

1–10 of 49

Are Funds Buying or Selling CDMO?

Are funds buying CDMO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CDMO
No. of Funds

Unveiling Avid Bioservices Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
6.9%
4,352,252
SC 13G
Feb 13, 2024
vanguard group inc
5.72%
3,617,873
SC 13G/A
Jan 26, 2024
altravue capital, llc
4.70%
2,974,333
SC 13G/A
Jan 25, 2024
state street corp
7.57%
4,784,239
SC 13G/A
Jan 08, 2024
blackrock inc.
8.4%
5,281,444
SC 13G/A
Jan 08, 2024
integrated core strategies (us) llc
4.8%
3,022,321
SC 13G/A
Dec 19, 2023
integrated core strategies (us) llc
5.1%
3,200,730
SC 13G
Feb 14, 2023
t. rowe price investment management, inc.
5.8%
3,607,653
SC 13G
Feb 09, 2023
state street corp
8.22%
5,123,806
SC 13G/A
Feb 09, 2023
vanguard group inc
6.98%
4,349,290
SC 13G/A

Recent SEC filings of Avid Bioservices Inc

View All Filings
Date Filed Form Type Document
Mar 20, 2024
8-K
Current Report
Mar 14, 2024
8-K
Current Report
Mar 12, 2024
8-K
Current Report
Mar 12, 2024
NT 10-Q
NT 10-Q
Mar 07, 2024
8-K
Current Report
Mar 06, 2024
8-K
Current Report
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 26, 2024
SC 13G/A
Major Ownership Report
Jan 25, 2024
SC 13G/A
Major Ownership Report

What is the Fair Value of CDMO?

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Cheap
or
Expensive?


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks

Peers (Alternatives to Avid Bioservices Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
42.3B
6.8B
19.31% -24.90%
-8.96
6.17
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.4B
1.8B
-0.33% -18.28%
-44.17
10.64
76.23% 61.08%
16.7B
2.4B
-4.10% -7.32%
99.73
6.91
15.42% 18.43%
12.8B
3.7B
-1.69% -18.94%
21.46
3.47
8.87% 75.42%
MID-CAP
7.1B
396.6M
-19.47% -8.81%
-13.34
17.78
425.83% 18.94%
5.4B
-
-20.51% 118.30%
-8.31
60.35
54.84% -34.79%
3.8B
270.6M
-13.09% 29.37%
-15.68
13.86
440.80% -27.84%
3.6B
240.7M
-7.70% 7.49%
-11.98
14.77
-1.03% -92.09%
3.0B
726.4M
-28.51% -9.28%
-48.93
4.13
40.45% 71.62%
SMALL-CAP
1.9B
398.2M
12.36% 9.77%
26.85
4.82
85.90% -14.05%
678.8M
983.7M
12.98% -18.87%
-1.25
0.69
-50.36% 17.16%
373.2M
881.7K
51.26% 463.55%
-8.37
466.16
-77.61% -5.33%
304.5M
4.9M
46.53% -11.16%
-2.25
62.57
-54.97% 51.72%
11.8M
2.1M
-13.49% -43.81%
-0.43
2.14
-13.45% 66.37%

Avid Bioservices Inc News

Latest updates
GlobeNewswire • 75 minutes ago
InvestorPlace • 07 Mar 2024 • 08:00 am
InvestorsObserver • 07 Mar 2024 • 08:00 am
CNN • 19 Feb 2024 • 05:58 am
Yahoo Finance • 30 Jan 2024 • 08:00 am

Avid Bioservices Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-32.7%25,39537,72639,79938,01834,75736,69231,22631,50826,10930,75427,60621,80621,06425,39212,55013,58518,31315,25417,05513,78110,178
Cost Of Revenue----------------12,80014,95314,16813,40711,7319,844
Gross Profit-213.8%-4,6654,1008,3919,8254,1479,1176,9849,0879,18611,3918,1436,2026,4188,544-1,2997853,3601,0863,6482,050334
Operating Expenses4.7%6,5576,263-7,1076,8316,382-5,8185,0334,460-4,0184,166--2,9963,889--3,2422,816
  S&GA Expenses4.7%6,5576,2637,5597,1076,8316,3825,9155,8185,0334,4605,0554,0184,1663,8253,5282,9963,5344,4593,5733,2422,816
EBITDA Margin-92.1%0.00*0.05*0.08*0.08*0.08*0.13*0.17*0.16*0.17*0.17*0.17*-0.09*---------
Interest Expenses3.9%8057757596207035185557187047031,160--4.00-------
Income Taxes-305.1%-2,378-5877572,069-2,086703-115,011------------67.00-44.00-173
Earnings Before Taxes-343.5%-11,887-2,6804482,530-3,2422,2675872,2483,5226,304-----4,768-2,104-430-167-1,183-2,363
EBT Margin-319.8%-0.08*-0.02*0.01*0.02*0.01*0.07*0.11*0.10*0.11*0.11*0.12*-0.13*---------
Net Income-354.3%-9,509-2,093-309461-1,1561,564115,5982,2483,5226,3041,9912,2072,2844,730-4,768-2,104-430-3,164336-1,139-1,451
Net Income Margin-294.3%-0.08*-0.02*0.00*0.83*0.88*0.98*1.07*0.12*0.13*0.13*0.12*0.06*---------
Free Cashflow91.5%-1,224-14,392-22,078-18,244-38,245-11,958-23,954-14,8292,978-11,14113,7132,452---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets2.8%45544245145044245143031430227126616811410610810510510278.0076.0080.00
  Current Assets6.0%10498.0011213214618118020320720120811663.0057.0060.0057.0056.0052.0051.0049.0052.00
    Cash Equivalents26.2%31.0025.0039.0060.0077.0011512615016416017071.0036.0028.0037.0031.0034.0029.0034.0028.0033.00
  Inventory-5.6%39.0041.0044.0045.0039.0030.0026.0021.0020.0015.0012.0012.0010.0010.0011.0010.008.008.007.009.0010.00
  Net PPE2.7%18718217716413911593.0069.0052.0045.0037.0032.0030.0028.0027.0027.0027.0026.0026.0026.0026.00
Liabilities7.6%271252262265261272255258251-18883.0064.0059.0066.0058.00--25.00--
  Current Liabilities20.1%77.0064.0074.0087.0082.0093.0076.0077.0070.0063.0071.0063.0044.0038.0044.0037.0034.0029.0023.0021.0023.00
Shareholder's Equity-3.6%18419118918518117917557.0051.0045.0078.0085.0049.0047.0042.0047.0049.0050.0053.0053.0055.00
  Retained Earnings-2.2%-442-432-430-430-430-429-431-546-549-552-559-561-564-566-571-566-564-563-560-560-559
  Additional Paid-In Capital0.4%626623620616612609606603600597638647613613613613613613614614615
Shares Outstanding0.2%63.0063.0063.0063.0062.0062.0062.0061.0061.0061.0058.0057.00---------
Float-----887---1,900---409---301---293
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations2293.9%6,099-2782,799-6,915-3,737-5,0346125,19210,603-6,94217,8605,18910,406-2,2733,047-6365,884-2,4685,648-3,082-6,713
  Share Based Compensation5.2%2,4662,3433,5512,7442,7861,8972,0282,1111,9421,2991,1009991,025730650595651603515458325
Cashflow From Investing48.1%-7,323-14,114-24,877-11,329-34,508-6,924-24,566-20,021-7,625-4,199-4,147-2,737-2,491-489-787-2,040-947-38.00-208-8022,746
Cashflow From Financing889.3%7,4007487048684009291631,1111,00591885,30832,778-462-5,2893,315-597-721-901-847-1,052-823

CDMO Income Statement

2023-10-31
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Oct. 31, 2023
Oct. 31, 2022
Oct. 31, 2023
Oct. 31, 2022
Income Statement [Abstract]    
Revenues$ 25,395$ 34,757$ 63,121$ 71,449
Cost of revenues30,06030,61063,68658,185
Gross profit (loss)(4,665)4,147(565)13,264
Operating expenses:    
Selling, general and administrative6,5576,83112,82013,213
Total operating expenses6,5576,83112,82013,213
Operating income (loss)(11,222)(2,684)(13,385)51
Interest expense(805)(703)(1,580)(1,221)
Other income, net140145398195
Net loss before income taxes(11,887)(3,242)(14,567)(975)
Income tax benefit(2,378)(2,086)(2,965)(1,383)
Net income (loss)(9,509)(1,156)(11,602)408
Comprehensive income (loss)$ (9,509)$ (1,156)$ (11,602)$ 408
Net income (loss) per share:    
Basic$ (0.15)$ (0.02)$ (0.18)$ 0.01
Diluted$ (0.15)$ (0.02)$ (0.18)$ 0.01
Weighted average common shares outstanding:    
Basic63,14962,20462,99462,054
Diluted63,14962,20462,99463,574

CDMO Balance Sheet

2023-10-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Oct. 31, 2023
Apr. 30, 2023
Current assets:  
Cash and cash equivalents$ 31,424$ 38,542
Accounts receivable, net13,37918,298
Contract assets10,8479,609
Inventory38,58343,908
Prepaid expenses and other current assets9,9722,094
Total current assets104,205112,451
Property and equipment, net187,174177,369
Operating lease right-of-use assets41,97342,772
Deferred tax assets116,617113,639
Other assets4,6734,473
Restricted cash0350
Total assets454,642451,054
Current liabilities:  
Accounts payable22,78424,593
Accrued compensation and benefits4,2448,780
Contract liabilities46,43737,352
Current portion of operating lease liabilities1,2631,358
Other current liabilities2,2091,626
Total current liabilities76,93773,709
Convertible senior notes, net141,154140,623
Operating lease liabilities, less current portion45,03645,690
Finance lease liabilities, less current portion7,8401,562
Total liabilities270,967261,584
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000 shares authorized; no shares issued and outstanding at respective dates00
Common stock, $0.001 par value; 150,000 shares authorized; 63,234 and 62,692 shares issued and outstanding at respective dates6363
Additional paid-in capital626,031620,224
Accumulated deficit(442,419)(430,817)
Total stockholders’ equity183,675189,470
Total liabilities and stockholders’ equity$ 454,642$ 451,054
CDMO
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services of biologics for the biotechnology and biopharmaceutical industries. The company offers various services, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. It also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
 CEO
 WEBSITEwww.avidbio.com
 EMPLOYEES365

Avid Bioservices Inc Frequently Asked Questions


What is the ticker symbol for Avid Bioservices Inc? What does CDMO stand for in stocks?

CDMO is the stock ticker symbol of Avid Bioservices Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avid Bioservices Inc (CDMO)?

As of Wed Mar 27 2024, market cap of Avid Bioservices Inc is 441.41 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDMO stock?

You can check CDMO's fair value in chart for subscribers.

What is the fair value of CDMO stock?

You can check CDMO's fair value in chart for subscribers. The fair value of Avid Bioservices Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avid Bioservices Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDMO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avid Bioservices Inc a good stock to buy?

The fair value guage provides a quick view whether CDMO is over valued or under valued. Whether Avid Bioservices Inc is cheap or expensive depends on the assumptions which impact Avid Bioservices Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDMO.

What is Avid Bioservices Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 27 2024, CDMO's PE ratio (Price to Earnings) is -38.55 and Price to Sales (PS) ratio is 3.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDMO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Avid Bioservices Inc's stock?

In the past 10 years, Avid Bioservices Inc has provided -0.081 (multiply by 100 for percentage) rate of return.